Lido Advisors’s Biolase, Inc. BIOL Stock Holding History

Lido Advisors’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1	Closed	-$5K	–	456
2018 Q1	$5K	Buy	+1	New	+$5.62K	﹤0.01%	394

Other funds holding BIOL

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PCM

Princeton Capital Management Red Bank, New Jersey $367M AUM 45.24% 1-Year Est. Return

Teton Advisors Rye, New York $142M AUM 42.07% 1-Year Est. Return

GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return

Lido Advisors's BIOL Position: Q2 2018 in Review

Lido Advisors sold out of Biolase, Inc. (BIOL) in Q2 2018, closing a stake of 1 share — an estimated $5K sold.

Lido Advisors first reported a position in BIOL in Q1 2018 and held it in 1 quarter. The position peaked at $5K in Q1 2018. 18 funds tracked by Wall St. Rank hold BIOL as of Q2 2018.

Lido Advisors reported no remaining Biolase, Inc. position as of Q2 2018 after selling out during the quarter.
Lido Advisors sold 1 Biolase, Inc. share in Q2 2018, an estimated $5K.
Lido Advisors first reported a position in Biolase, Inc. in Q1 2018 and held it in 1 quarter.
Lido Advisors's Biolase, Inc. position peaked at $5K in Q1 2018.
18 funds tracked by Wall St. Rank held Biolase, Inc. as of Q2 2018.

Based on Lido Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.